Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 2/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119868 | 0.88 | HRH4 (0.35) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL25874026 | 0.87 | KHK (0.36) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL25874033 | 0.84 | KHK (0.35) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL25874012 | 0.82 | KHK (0.34) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL25874124 | 0.81 | KHK (0.37) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL20119786 | 0.76 | HRH4 (0.35) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL20119772 | 0.75 | HRH4 (0.37) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL20119527 | 0.75 | HRH4 (0.37) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL20119819 | 0.73 | CTSL (0.35) | KHKTRPM5HRH4KDM1AMAOB | |
| SCHEMBL20119715 | 0.73 | TRPM5 (0.36) | KHKTRPM5HRH4KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KHK 2342/4885TRPM5 4390/4885HRH4 4263/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | KHK 2342/4885TRPM5 4390/4885HRH4 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.